NCT02074579 - A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Irritable Bowel Syndrome in Females

Interventions

DRUG

TU-100

15g daily, orally as 5g three times daily for 4 consecutive weeks

DRUG

Placebo

Matching placebo given 5g three times daily orally for 4 consecutive weeks

Trial Locations (1)

Oppenheimer Family Center for Neurobiology of Stress Division of Digestive Diseases David Geffen School of Medicine at UCLA, Los Angeles